![](/images/graphics-bg.png)
Everolimus-Based Therapy versus Chemotherapy among Patients with HR+HER2− Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study
المؤلفون المشاركون
Hao, Yanni
Li, Nanxin
Xie, Jipan
Lin, Peggy L.
Koo, Valerie
Ohashi, Erika
Wu, Eric Q.
المصدر
International Journal of Breast Cancer
العدد
المجلد 2015، العدد 2015 (31 ديسمبر/كانون الأول 2015)، ص ص. 1-9، 9ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2015-05-20
دولة النشر
مصر
عدد الصفحات
9
التخصصات الرئيسية
الملخص EN
Objective.
To compare the real-world effectiveness of everolimus-based therapy and chemotherapy in postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative (HR+/HER2−) metastatic breast cancer (mBC).
Methods.
This retrospective chart review examined a nationwide sample of postmenopausal HR+/HER2− mBC women in community-based oncology practices.
Patients received everolimus-based therapy or chemotherapy for mBC between 07/01/2012 and 04/15/2013, after failure of a non-steroidal aromatase inhibitor.
Overall survival (OS), progression-free survival (PFS), and time on treatment (TOT) were compared using Kaplan-Meier analysis and Cox proportional hazards models adjusting for line of therapy and baseline characteristics.
Results.
234 and 137 patients received everolimus-based therapy and chemotherapy.
Patients treated with everolimus-based therapy tended to have less aggressive mBC than patients treated with chemotherapy.
Multivariate-adjusted Cox models showed that everolimus-based therapy was associated with significantly longer OS [hazard ratio (HR) = 0.37, 95% confidence interval (CI): 0.22–0.63], PFS (HR = 0.70, 95% CI = 0.50–0.97), and TOT (HR = 0.34, 95% CI: 0.25–0.45) than chemotherapy.
Adjusted comparative effectiveness results were generally consistent across lines of therapy.
Conclusion.
In this retrospective chart review of postmenopausal HR+/HER2− mBC patients, treatment with everolimus-based therapy was associated with longer OS, PFS, and TOT than chemotherapy.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Li, Nanxin& Hao, Yanni& Xie, Jipan& Lin, Peggy L.& Koo, Valerie& Ohashi, Erika…[et al.]. 2015. Everolimus-Based Therapy versus Chemotherapy among Patients with HR+HER2− Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study. International Journal of Breast Cancer،Vol. 2015, no. 2015, pp.1-9.
https://search.emarefa.net/detail/BIM-1065259
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Li, Nanxin…[et al.]. Everolimus-Based Therapy versus Chemotherapy among Patients with HR+HER2− Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study. International Journal of Breast Cancer No. 2015 (2015), pp.1-9.
https://search.emarefa.net/detail/BIM-1065259
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Li, Nanxin& Hao, Yanni& Xie, Jipan& Lin, Peggy L.& Koo, Valerie& Ohashi, Erika…[et al.]. Everolimus-Based Therapy versus Chemotherapy among Patients with HR+HER2− Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study. International Journal of Breast Cancer. 2015. Vol. 2015, no. 2015, pp.1-9.
https://search.emarefa.net/detail/BIM-1065259
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1065259
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)